Venclexta 50 MG tablet UD 7S
Ended Awarded Last action
- Contract number
- SPE2DR26F9MA4
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $2,611
Award facts
- Contract value 100% obligated
- $2,611.32 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on January 20, 2026, for the supply of Venclexta 50 mg tablets in unit dose packages of seven at a firm fixed price of $2,611.32. This non-set-aside, competitively awarded delivery order is scheduled for completion by February 10, 2026, with performance taking place at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a task order under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which is valued at up to $999,999,999.00 through December 31, 2031. This comprehensive IDC serves as the primary vehicle for delivering pharmaceutical products and medical supplies to support military healthcare programs globally, encompassing specialty medications, brand-name and generic drugs, vaccines, and related medical commodities across multiple therapeutic domains.
AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical vendor for federal medical procurement, competes on a full and open basis for DLA contracts that support military treatment facilities and veterans' healthcare programs. The company's extensive portfolio of federal contract awards demonstrates its capability to efficiently fulfill government requirements for essential pharmaceutical products, including oncology medications such as Venclexta, diabetes treatments, neurological therapies, pain management pharmaceuticals, and antibiotics. Through its parent company Cencora, Inc., the contractor maintains significant federal contracting relationships with the DLA, Department of Veterans Affairs, and other government healthcare systems, positioning it as a key supplier within the military medical supply chain.
Quick answers
Who was awarded contract SPE2DR26F9MA4?
SPE2DR26F9MA4 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 20, 2026.
How much is contract SPE2DR26F9MA4 worth?
The government has obligated $2,611 on SPE2DR26F9MA4.
Is contract SPE2DR26F9MA4 an order under another contract?
Yes. SPE2DR26F9MA4 is a delivery order under SPE2DR25D2206, an indefinite delivery contract.
Was contract SPE2DR26F9MA4 competed?
The extent of competition for SPE2DR26F9MA4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award